Table 1.
Phase I and II studies assessing single dose stereotactic irradiation to the spine.
| Author, year | No. patients/no. lesions | Prior RT | Dose/coverage | Constraints/dose to spinal cord | Histology | Median F/U (months) | Local control |
|---|---|---|---|---|---|---|---|
| Gerszten et al., 2005 | 50/68 | 48/68 | 12.5–22.5 Gy (mean, 19 Gy)/80% IDL | 13 Gy (max. dose actually received) | Breast | 16 | 100% |
| Gerszten et al., 2005 | 28/36 | 23/36 | 17.5–25 Gy (mean, 21.9 Gy)/80% IDL | 13.1 Gy (max. dose actually received) | Melanoma | 13 | 93% |
| Gerszten et al., 2006 | 77/87 | 70/87 | 15–25 Gy (mean, 20 Gy)/80% IDL | 12 Gy (max. dose actually received) | Lung | 16 | 100% |
| Gerszten et al., 2007 | 393/500 | 344/500 | 12.5–25 Gy (mean, 20 Gy)/80% IDL | NR (mean volume of spinal canal dose >8 Gy 0.6 cm3 | Mixed | 21 | 88% |
| Yamada et al., 2008 | 93/103 | 0/103 | 18–24 Gy/100% IDL | 14 Gy (max. dose) | Mixed | 15 | 90% |
| Amdur et al., 2009 | 21/25 | 12/25 | 15 Gy/95% PTV | ≤12 Gy to 0.1 mL (no previous RT) ≤5 Gy to 0.5 mL (if previous RT) |
Mixed | 8 | 95% |
| Yamada et al., 2011 | 412/362 | 0/363 | 18–24 Gy/100% IDL | 14–15 Gy (max point dose) | Mixed | 36 | 90% (98% in breast and prostate) |
| Garg et al., 2012 | 61/63 | 0/63 | 16–24 Gy/80–90% | ≤10 Gy to 0.01 cm3 ≤12 Gy (spinal cord + 2 mm) |
Mixed (renal versus non-renal) | 19.7 | 88% |
| Ryu et al., 2014 | 39/NR | NR | 16 Gy/90% PTV (accepted >80%) | ≤10% partial spinal cord, max 10 Gy ≤0.35 cm3 absolute spinal cord, max 10 Gy |
NR (no exclusion criteria for histology) | NR | NR |
IDL, isodose line.